SLC5A2 and heart failure: A systematic review and meta-analysis by Neuen et al. [48] (six studies, n=51743), reported that SGLT-2 inhibitors with/without metformin reduced major adverse cardiovascular events (MACE) (HR 0.93, 95% CI 0.87–1.00), and hospitalization for heart failure (HHF) or cardiovascular death (HR 0.79, 95% CI 0.73–0.86).